Go to
JCI Insight
Citations to this article
Abstract
Thrombocytopenia, an abnormally low number of circulating platelets, results from inadequate platelet production, splenic platelet sequestration, or accelerated platelet clearance. Platelet transfusions are now the cornerstone for treating thrombocytopenia. With an ever-expanding demand for platelets, and with many patients having an inadequate response to platelet transfusions, new strategies are needed to treat thrombocytopenia. In this issue of the JCI, Fuentes et al. present provocative data regarding the use of direct megakaryocyte infusions as a novel approach to manage this vexing clinical problem.
Authors
Andrew D. Leavitt
Citation information
Citations to this article (3)
| Title and authors | Publication | Year |
|---|---|---|
|
Current Challenges in the Development of Platelet-Rich Plasma-Based Therapies.
Mercader-Ruiz J, Beitia M, Delgado D, Sánchez P, Porras B, Gimeno I, González S, Benito-Lopez F, Basabe-Desmonts L, Sánchez M |
BioMed research international | 2024 |
|
A novel strategy for the screening for platelet refractoriness: prospects and limitations
VR Arruda |
Revista Brasileira de Hematologia e Hemoterapia | 2013 |
|
Platelets in lung biology
AS Weyrich, GA Zimmerman |
Annual Review of Physiology | 2012 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)